SCHEMBL6492973

SCHEMBL6492973

Cc1ccc(C2=C(C(=O)Nc3ccc(N(CCc4csc(NC(=O)OC(C)(C)C)n4)C(=O)O)cc3)CCCC2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SREBF2 Q12772 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
CYP17A1 P05093 1/20 0.35
HDAC1 Q13547 8/20 0.35
HDAC6 Q9UBN7 6/20 0.35
HDAC3 O15379 6/20 0.34
HDAC10 Q969S8 6/20 0.34
HDAC2 Q92769 5/20 0.34
HDAC8 Q9BY41 5/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PTPRB P23467 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499439 0.93 SREBF2 (0.38) SREBF2SIRT1CYP17A1HDAC1HDAC6
SCHEMBL6500346 0.91 SREBF2 (0.35) SREBF2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6487517 0.87 TP53 (0.39) SREBF2SIRT1HDAC1HDAC6MAPT
SCHEMBL6490643 0.85 SREBF2 (0.36) SREBF2SIRT1CYP17A1HDAC1HDAC6
SCHEMBL6496973 0.85 SREBF2 (0.41) SREBF2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6499741 0.84 SREBF2 (0.40) SREBF2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6794499 0.83 CYP3A4 (0.40) SREBF2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6501137 0.82 PDE5A (0.39) SREBF2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6500413 0.81 TP53 (0.35) CYP1A2CYP3A4CYP2C9CYP2C19CYP17A1
SCHEMBL6489597 0.81 MAPT (0.40) SREBF2CYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 SREBF2 285/4885CYP1A2 115/4885CYP3A4 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.